| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 88 | 2022 | 529 | 13.580 |
Why?
|
| Insulin | 31 | 2022 | 619 | 5.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 45 | 2022 | 1085 | 4.520 |
Why?
|
| Blood Glucose | 35 | 2022 | 631 | 4.040 |
Why?
|
| Diabetic Retinopathy | 28 | 2022 | 110 | 3.390 |
Why?
|
| Hypoglycemic Agents | 24 | 2022 | 362 | 3.160 |
Why?
|
| Diabetic Angiopathies | 20 | 2020 | 203 | 3.030 |
Why?
|
| Fenofibrate | 17 | 2022 | 23 | 2.970 |
Why?
|
| Insulin Infusion Systems | 16 | 2022 | 27 | 2.760 |
Why?
|
| Hypolipidemic Agents | 12 | 2021 | 82 | 2.360 |
Why?
|
| Cardiovascular Diseases | 28 | 2021 | 940 | 2.270 |
Why?
|
| Lipoproteins | 15 | 2019 | 161 | 2.000 |
Why?
|
| Biomarkers | 32 | 2021 | 1593 | 1.670 |
Why?
|
| Retinal Vessels | 14 | 2022 | 74 | 1.670 |
Why?
|
| Insulin Resistance | 8 | 2022 | 241 | 1.670 |
Why?
|
| Hypoglycemia | 9 | 2022 | 72 | 1.430 |
Why?
|
| Lipoproteins, LDL | 16 | 2015 | 343 | 1.410 |
Why?
|
| Adult | 87 | 2022 | 21403 | 1.320 |
Why?
|
| Humans | 157 | 2022 | 68618 | 1.240 |
Why?
|
| MicroRNAs | 3 | 2021 | 447 | 1.180 |
Why?
|
| Male | 110 | 2022 | 37321 | 1.180 |
Why?
|
| Australia | 17 | 2022 | 235 | 1.170 |
Why?
|
| Female | 112 | 2022 | 38074 | 1.150 |
Why?
|
| Glucose Clamp Technique | 4 | 2022 | 24 | 1.100 |
Why?
|
| Telomere | 7 | 2022 | 59 | 1.080 |
Why?
|
| Middle Aged | 71 | 2022 | 21147 | 1.070 |
Why?
|
| Lipoproteins, HDL | 9 | 2017 | 113 | 1.060 |
Why?
|
| Pre-Eclampsia | 9 | 2020 | 202 | 1.060 |
Why?
|
| C-Reactive Protein | 14 | 2019 | 180 | 1.030 |
Why?
|
| Telomere Shortening | 4 | 2022 | 8 | 0.980 |
Why?
|
| Diabetic Nephropathies | 9 | 2019 | 161 | 0.970 |
Why?
|
| Albuminuria | 10 | 2019 | 171 | 0.880 |
Why?
|
| Apolipoproteins | 4 | 2019 | 51 | 0.870 |
Why?
|
| Risk Factors | 47 | 2022 | 5731 | 0.870 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2022 | 101 | 0.860 |
Why?
|
| Uric Acid | 3 | 2021 | 37 | 0.830 |
Why?
|
| Pregnancy in Diabetics | 7 | 2020 | 70 | 0.830 |
Why?
|
| Triglycerides | 9 | 2017 | 184 | 0.800 |
Why?
|
| Oxidative Stress | 8 | 2016 | 718 | 0.780 |
Why?
|
| Health Services, Indigenous | 1 | 2020 | 2 | 0.750 |
Why?
|
| Biological Variation, Individual | 1 | 2020 | 2 | 0.750 |
Why?
|
| Inflammation | 8 | 2019 | 1030 | 0.740 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 1293 | 0.730 |
Why?
|
| Blood Glucose Self-Monitoring | 11 | 2022 | 62 | 0.730 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 191 | 0.720 |
Why?
|
| Prospective Studies | 32 | 2022 | 3705 | 0.720 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 365 | 0.700 |
Why?
|
| Rural Health Services | 1 | 2020 | 101 | 0.680 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2019 | 26 | 0.680 |
Why?
|
| Serpins | 3 | 2019 | 205 | 0.650 |
Why?
|
| Fibroblast Growth Factors | 5 | 2018 | 51 | 0.650 |
Why?
|
| Aged | 36 | 2022 | 14862 | 0.640 |
Why?
|
| Platelet Count | 2 | 2009 | 100 | 0.640 |
Why?
|
| Cross-Sectional Studies | 22 | 2019 | 2279 | 0.630 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 75 | 0.620 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 694 | 0.610 |
Why?
|
| Adolescent | 33 | 2022 | 8912 | 0.600 |
Why?
|
| Eye Proteins | 2 | 2019 | 160 | 0.580 |
Why?
|
| Diabetes Complications | 7 | 2020 | 249 | 0.570 |
Why?
|
| Glycation End Products, Advanced | 6 | 2021 | 125 | 0.560 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 848 | 0.550 |
Why?
|
| Magnetic Resonance Spectroscopy | 11 | 2015 | 346 | 0.510 |
Why?
|
| Carotid Intima-Media Thickness | 6 | 2021 | 54 | 0.510 |
Why?
|
| Young Adult | 22 | 2021 | 5717 | 0.510 |
Why?
|
| Cohort Studies | 18 | 2022 | 2358 | 0.500 |
Why?
|
| Leukocytes | 5 | 2022 | 99 | 0.500 |
Why?
|
| Metformin | 4 | 2021 | 63 | 0.490 |
Why?
|
| Apolipoprotein A-I | 5 | 2014 | 29 | 0.480 |
Why?
|
| Glucose | 5 | 2022 | 307 | 0.460 |
Why?
|
| Cholesterol, LDL | 9 | 2017 | 161 | 0.450 |
Why?
|
| Cholesterol, HDL | 9 | 2022 | 112 | 0.450 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 767 | 0.420 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 3259 | 0.420 |
Why?
|
| Deoxyglucose | 1 | 2011 | 32 | 0.400 |
Why?
|
| Child | 17 | 2022 | 6405 | 0.400 |
Why?
|
| Lipids | 7 | 2021 | 298 | 0.370 |
Why?
|
| Kidney Diseases | 3 | 2021 | 307 | 0.370 |
Why?
|
| Renal Dialysis | 2 | 2009 | 174 | 0.360 |
Why?
|
| Arterioles | 5 | 2021 | 40 | 0.360 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 191 | 0.360 |
Why?
|
| Infusions, Subcutaneous | 1 | 2010 | 5 | 0.360 |
Why?
|
| Incidence | 12 | 2021 | 1603 | 0.360 |
Why?
|
| Creatinine | 4 | 2017 | 243 | 0.350 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 43 | 0.350 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 219 | 0.340 |
Why?
|
| Disease Progression | 10 | 2020 | 1038 | 0.340 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2019 | 17 | 0.340 |
Why?
|
| Endothelium, Vascular | 3 | 2008 | 371 | 0.330 |
Why?
|
| Glomerular Filtration Rate | 7 | 2021 | 274 | 0.330 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 191 | 0.330 |
Why?
|
| Longitudinal Studies | 9 | 2020 | 1054 | 0.330 |
Why?
|
| Hyperglycemia | 4 | 2017 | 158 | 0.320 |
Why?
|
| Atherosclerosis | 3 | 2017 | 204 | 0.310 |
Why?
|
| Blood Pressure | 10 | 2018 | 1451 | 0.300 |
Why?
|
| Algorithms | 2 | 2011 | 1196 | 0.290 |
Why?
|
| Kidney | 3 | 2021 | 945 | 0.290 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2005 | 58 | 0.290 |
Why?
|
| Blood Platelets | 1 | 2008 | 284 | 0.290 |
Why?
|
| Cross-Over Studies | 7 | 2022 | 260 | 0.280 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2010 | 45 | 0.280 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2010 | 52 | 0.280 |
Why?
|
| Molecular Weight | 3 | 2021 | 358 | 0.280 |
Why?
|
| Case-Control Studies | 10 | 2020 | 1553 | 0.280 |
Why?
|
| Fluorescence | 2 | 2021 | 104 | 0.280 |
Why?
|
| Vitamin D | 4 | 2022 | 516 | 0.280 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2015 | 195 | 0.270 |
Why?
|
| Retina | 4 | 2017 | 252 | 0.260 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2005 | 12 | 0.260 |
Why?
|
| Vasculitis | 1 | 2005 | 33 | 0.260 |
Why?
|
| Erythrocyte Membrane | 1 | 2005 | 20 | 0.260 |
Why?
|
| Retinal Artery | 3 | 2011 | 10 | 0.250 |
Why?
|
| Smoking | 3 | 2021 | 1452 | 0.250 |
Why?
|
| Exercise | 3 | 2022 | 658 | 0.250 |
Why?
|
| Pregnancy | 10 | 2022 | 2334 | 0.240 |
Why?
|
| Skin | 4 | 2021 | 451 | 0.240 |
Why?
|
| Vitamin D Deficiency | 3 | 2022 | 292 | 0.230 |
Why?
|
| Dyslipidemias | 2 | 2015 | 98 | 0.230 |
Why?
|
| Mortality | 3 | 2019 | 163 | 0.230 |
Why?
|
| PPAR alpha | 2 | 2014 | 31 | 0.230 |
Why?
|
| Lipocalin-2 | 2 | 2020 | 19 | 0.220 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 30 | 0.220 |
Why?
|
| Finland | 2 | 2020 | 13 | 0.220 |
Why?
|
| New Zealand | 2 | 2020 | 28 | 0.220 |
Why?
|
| Insulin-Secreting Cells | 2 | 2021 | 41 | 0.220 |
Why?
|
| Injections | 2 | 2020 | 119 | 0.220 |
Why?
|
| Double-Blind Method | 8 | 2021 | 1738 | 0.220 |
Why?
|
| Glycoproteins | 1 | 2004 | 238 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1046 | 0.210 |
Why?
|
| Aryldialkylphosphatase | 3 | 2008 | 11 | 0.210 |
Why?
|
| Insulin Antibodies | 1 | 2022 | 2 | 0.210 |
Why?
|
| Cholesterol | 8 | 2015 | 331 | 0.210 |
Why?
|
| Insulins | 1 | 2022 | 5 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 296 | 0.210 |
Why?
|
| Treatment Outcome | 9 | 2021 | 7029 | 0.210 |
Why?
|
| Liver | 3 | 2015 | 1118 | 0.200 |
Why?
|
| Microvessels | 4 | 2017 | 43 | 0.200 |
Why?
|
| Fasting | 2 | 2020 | 75 | 0.200 |
Why?
|
| Microcirculation | 4 | 2015 | 77 | 0.200 |
Why?
|
| Resistance Training | 1 | 2022 | 29 | 0.200 |
Why?
|
| Myeloblastin | 1 | 2021 | 2 | 0.200 |
Why?
|
| Hong Kong | 4 | 2021 | 11 | 0.200 |
Why?
|
| Leukocyte Elastase | 1 | 2021 | 19 | 0.190 |
Why?
|
| C-Peptide | 1 | 2021 | 23 | 0.190 |
Why?
|
| Injections, Subcutaneous | 1 | 2021 | 87 | 0.190 |
Why?
|
| Diabetic Neuropathies | 1 | 2021 | 33 | 0.190 |
Why?
|
| Circulating MicroRNA | 1 | 2021 | 9 | 0.190 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2020 | 4 | 0.190 |
Why?
|
| Chronic Disease | 4 | 2020 | 1330 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4848 | 0.190 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 12 | 0.190 |
Why?
|
| Cerebrovascular Disorders | 3 | 2007 | 182 | 0.180 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 1465 | 0.180 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 37 | 0.180 |
Why?
|
| Autoimmunity | 1 | 2021 | 118 | 0.180 |
Why?
|
| Oxidation-Reduction | 5 | 2008 | 567 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 84 | 0.180 |
Why?
|
| Forecasting | 1 | 2021 | 277 | 0.180 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2020 | 58 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 209 | 0.180 |
Why?
|
| Age Factors | 3 | 2021 | 1864 | 0.170 |
Why?
|
| Haptoglobins | 1 | 2019 | 12 | 0.170 |
Why?
|
| Inventions | 1 | 2019 | 7 | 0.170 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 244 | 0.170 |
Why?
|
| Prevalence | 5 | 2020 | 1619 | 0.170 |
Why?
|
| Vitamin E | 1 | 1999 | 55 | 0.170 |
Why?
|
| Awareness | 1 | 2019 | 81 | 0.170 |
Why?
|
| Patient Care Management | 1 | 2019 | 40 | 0.170 |
Why?
|
| Time Factors | 9 | 2021 | 4655 | 0.160 |
Why?
|
| Prognosis | 8 | 2019 | 2093 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 434 | 0.160 |
Why?
|
| Eggs | 1 | 2018 | 21 | 0.160 |
Why?
|
| Research Personnel | 1 | 2019 | 83 | 0.160 |
Why?
|
| Methionine | 2 | 2008 | 36 | 0.160 |
Why?
|
| Diet, Reducing | 1 | 2018 | 46 | 0.160 |
Why?
|
| Career Choice | 1 | 2019 | 98 | 0.150 |
Why?
|
| Regression Analysis | 7 | 2018 | 737 | 0.150 |
Why?
|
| Independent Living | 1 | 2018 | 44 | 0.150 |
Why?
|
| Antioxidants | 3 | 2005 | 304 | 0.150 |
Why?
|
| Carotid Arteries | 3 | 2021 | 110 | 0.150 |
Why?
|
| Retinal Vein | 2 | 2008 | 4 | 0.150 |
Why?
|
| Lipoproteins, VLDL | 4 | 2009 | 32 | 0.150 |
Why?
|
| High-Intensity Interval Training | 1 | 2017 | 2 | 0.150 |
Why?
|
| Adipokines | 1 | 2017 | 20 | 0.150 |
Why?
|
| Pancreas, Artificial | 1 | 2017 | 4 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 183 | 0.150 |
Why?
|
| Urban Health | 1 | 2017 | 49 | 0.150 |
Why?
|
| Retinol-Binding Proteins, Plasma | 2 | 2017 | 12 | 0.150 |
Why?
|
| Glycemic Index | 1 | 2017 | 28 | 0.150 |
Why?
|
| Self-Management | 1 | 2018 | 82 | 0.140 |
Why?
|
| Patient Selection | 2 | 2019 | 592 | 0.140 |
Why?
|
| Logistic Models | 2 | 2018 | 1420 | 0.140 |
Why?
|
| Phthalic Acids | 1 | 2017 | 28 | 0.140 |
Why?
|
| Vasodilation | 1 | 2017 | 85 | 0.140 |
Why?
|
| New South Wales | 5 | 2020 | 10 | 0.140 |
Why?
|
| Hyperlipidemias | 2 | 2009 | 90 | 0.140 |
Why?
|
| Students, Medical | 1 | 2019 | 210 | 0.140 |
Why?
|
| Self Report | 1 | 2018 | 371 | 0.140 |
Why?
|
| Retinal Neurons | 1 | 2016 | 9 | 0.140 |
Why?
|
| Apolipoproteins B | 2 | 2014 | 29 | 0.130 |
Why?
|
| Sex Characteristics | 3 | 2010 | 295 | 0.130 |
Why?
|
| Muscle Strength | 1 | 2016 | 62 | 0.130 |
Why?
|
| Weight Loss | 1 | 2018 | 319 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 283 | 0.130 |
Why?
|
| Hand Strength | 1 | 2016 | 47 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 310 | 0.130 |
Why?
|
| Environmental Pollutants | 1 | 2017 | 180 | 0.130 |
Why?
|
| Polymorphism, Genetic | 3 | 2006 | 301 | 0.130 |
Why?
|
| Malnutrition | 1 | 2015 | 28 | 0.130 |
Why?
|
| Physicians | 1 | 2019 | 324 | 0.130 |
Why?
|
| E-Selectin | 3 | 2019 | 44 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2017 | 269 | 0.120 |
Why?
|
| Puberty | 1 | 2014 | 10 | 0.120 |
Why?
|
| Apolipoproteins C | 2 | 2005 | 15 | 0.120 |
Why?
|
| Blood Proteins | 2 | 2005 | 94 | 0.120 |
Why?
|
| Glycosylation | 3 | 2010 | 185 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 73 | 0.120 |
Why?
|
| Adiposity | 1 | 2015 | 88 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 87 | 0.120 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 94 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 931 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 28 | 0.120 |
Why?
|
| Critical Care | 1 | 2016 | 263 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1664 | 0.120 |
Why?
|
| Animals | 10 | 2017 | 20881 | 0.110 |
Why?
|
| Copper | 1 | 2015 | 149 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2014 | 57 | 0.110 |
Why?
|
| Pyruvaldehyde | 2 | 2010 | 3 | 0.110 |
Why?
|
| Pericytes | 1 | 2014 | 81 | 0.110 |
Why?
|
| Carotenoids | 2 | 2011 | 45 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2014 | 2673 | 0.110 |
Why?
|
| Life Style | 2 | 2016 | 338 | 0.110 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2012 | 48 | 0.110 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 75 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2005 | 483 | 0.100 |
Why?
|
| Fractals | 2 | 2009 | 5 | 0.100 |
Why?
|
| Fascia | 1 | 2012 | 17 | 0.100 |
Why?
|
| Hypertension | 4 | 2014 | 1535 | 0.100 |
Why?
|
| Tunica Intima | 3 | 2008 | 59 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 260 | 0.100 |
Why?
|
| Obesity | 2 | 2018 | 1076 | 0.100 |
Why?
|
| Antigen-Antibody Complex | 2 | 2010 | 175 | 0.100 |
Why?
|
| Foot | 1 | 2012 | 66 | 0.100 |
Why?
|
| Insulin, Regular, Human | 2 | 2022 | 4 | 0.100 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2017 | 17 | 0.100 |
Why?
|
| Venules | 2 | 2022 | 8 | 0.100 |
Why?
|
| Biological Specimen Banks | 2 | 2021 | 38 | 0.100 |
Why?
|
| Sex Factors | 2 | 2014 | 1266 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2015 | 880 | 0.090 |
Why?
|
| Veterans | 2 | 2019 | 904 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 98 | 0.090 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 26 | 0.090 |
Why?
|
| Placebos | 3 | 2020 | 195 | 0.090 |
Why?
|
| Tunica Media | 2 | 2008 | 33 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 425 | 0.090 |
Why?
|
| Body Mass Index | 5 | 2017 | 867 | 0.080 |
Why?
|
| Thiazoles | 1 | 2009 | 95 | 0.080 |
Why?
|
| beta Carotene | 2 | 2011 | 16 | 0.080 |
Why?
|
| Sex Distribution | 2 | 2014 | 274 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2009 | 96 | 0.080 |
Why?
|
| Fasciitis, Plantar | 1 | 2008 | 3 | 0.080 |
Why?
|
| Leucine | 1 | 2008 | 41 | 0.080 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 2550 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2005 | 101 | 0.080 |
Why?
|
| Lactic Acid | 2 | 2019 | 86 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 234 | 0.080 |
Why?
|
| Norway | 2 | 2019 | 18 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2008 | 144 | 0.080 |
Why?
|
| Thrombin | 1 | 2008 | 117 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 284 | 0.080 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2008 | 112 | 0.070 |
Why?
|
| Thrombosis | 1 | 2009 | 218 | 0.070 |
Why?
|
| Registries | 2 | 2021 | 733 | 0.070 |
Why?
|
| Quality of Life | 2 | 2018 | 1515 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2008 | 627 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2019 | 7277 | 0.070 |
Why?
|
| Macrophages | 1 | 2011 | 647 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 212 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2010 | 384 | 0.070 |
Why?
|
| Risk | 3 | 2015 | 563 | 0.070 |
Why?
|
| Fibrinogen | 2 | 2005 | 87 | 0.070 |
Why?
|
| Capillaries | 2 | 2014 | 105 | 0.070 |
Why?
|
| Alanine Transaminase | 2 | 2017 | 137 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 1851 | 0.070 |
Why?
|
| Aging | 1 | 2012 | 911 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2007 | 198 | 0.060 |
Why?
|
| Hemostasis | 1 | 2005 | 32 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 85 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2005 | 1040 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 807 | 0.060 |
Why?
|
| Stroke | 5 | 2014 | 2163 | 0.060 |
Why?
|
| Lysophosphatidylcholines | 1 | 2005 | 11 | 0.060 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Ketones | 1 | 2005 | 24 | 0.060 |
Why?
|
| Fibrinolysis | 1 | 2005 | 55 | 0.060 |
Why?
|
| Renin | 1 | 2005 | 96 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2005 | 80 | 0.060 |
Why?
|
| Collagen | 1 | 2008 | 636 | 0.060 |
Why?
|
| Coronary Artery Disease | 2 | 2018 | 696 | 0.060 |
Why?
|
| Phospholipids | 1 | 2005 | 108 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 96 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2005 | 97 | 0.060 |
Why?
|
| Chromatography, Affinity | 1 | 2004 | 73 | 0.060 |
Why?
|
| Cattle | 2 | 2009 | 475 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 1753 | 0.060 |
Why?
|
| Photography | 3 | 2009 | 37 | 0.060 |
Why?
|
| Lipoproteins, IDL | 1 | 2003 | 8 | 0.060 |
Why?
|
| Aorta | 1 | 2005 | 316 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.060 |
Why?
|
| Cholesterol, VLDL | 1 | 2003 | 17 | 0.060 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2003 | 6 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2003 | 12 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 1 | 2003 | 20 | 0.050 |
Why?
|
| Swine, Miniature | 1 | 2003 | 45 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2003 | 45 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2003 | 50 | 0.050 |
Why?
|
| Particle Size | 3 | 2010 | 201 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 290 | 0.050 |
Why?
|
| Diabetic Foot | 1 | 2002 | 33 | 0.050 |
Why?
|
| Telomere Homeostasis | 1 | 2022 | 6 | 0.050 |
Why?
|
| Visual Field Tests | 1 | 2022 | 8 | 0.050 |
Why?
|
| Calcifediol | 1 | 2022 | 70 | 0.050 |
Why?
|
| NADPH Oxidases | 2 | 2014 | 80 | 0.050 |
Why?
|
| Mother-Child Relations | 1 | 2022 | 43 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2002 | 169 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2003 | 112 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2022 | 10 | 0.050 |
Why?
|
| Visual Fields | 1 | 2022 | 41 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 91 | 0.050 |
Why?
|
| Pupil | 1 | 2022 | 51 | 0.050 |
Why?
|
| Perindopril | 3 | 2007 | 4 | 0.050 |
Why?
|
| Linear Models | 2 | 2017 | 521 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2013 | 85 | 0.050 |
Why?
|
| Meals | 1 | 2021 | 14 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 134 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 358 | 0.050 |
Why?
|
| Needlestick Injuries | 1 | 2020 | 10 | 0.050 |
Why?
|
| Blood Specimen Collection | 1 | 2020 | 17 | 0.050 |
Why?
|
| Fingers | 1 | 2020 | 39 | 0.050 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 58 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2014 | 432 | 0.040 |
Why?
|
| Diet | 1 | 2003 | 514 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 16 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2014 | 499 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2019 | 38 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 3 | 2005 | 167 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 94 | 0.040 |
Why?
|
| United States | 3 | 2019 | 7367 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2005 | 665 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2020 | 123 | 0.040 |
Why?
|
| Nitrites | 1 | 1999 | 53 | 0.040 |
Why?
|
| Body Weight | 2 | 2017 | 554 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 73 | 0.040 |
Why?
|
| Financial Support | 1 | 2019 | 5 | 0.040 |
Why?
|
| Rats | 3 | 2015 | 5300 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 772 | 0.040 |
Why?
|
| Cell Count | 1 | 1999 | 248 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 29 | 0.040 |
Why?
|
| Smokers | 1 | 2021 | 200 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 157 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 792 | 0.040 |
Why?
|
| Selectins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1999 | 304 | 0.040 |
Why?
|
| F2-Isoprostanes | 1 | 2018 | 14 | 0.040 |
Why?
|
| Anticholesteremic Agents | 1 | 2018 | 49 | 0.040 |
Why?
|
| Endothelin-1 | 1 | 1999 | 122 | 0.040 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 9 | 0.040 |
Why?
|
| Functional Laterality | 2 | 2009 | 240 | 0.040 |
Why?
|
| Bolivia | 1 | 2017 | 3 | 0.040 |
Why?
|
| Resistin | 1 | 2017 | 9 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 186 | 0.040 |
Why?
|
| Schools, Medical | 1 | 2019 | 157 | 0.040 |
Why?
|
| Home Care Services | 1 | 2018 | 84 | 0.040 |
Why?
|
| Ketone Bodies | 1 | 2017 | 5 | 0.040 |
Why?
|
| South Australia | 1 | 2017 | 19 | 0.040 |
Why?
|
| Victoria | 1 | 2017 | 8 | 0.040 |
Why?
|
| Mice | 3 | 2014 | 8474 | 0.040 |
Why?
|
| Adiponectin | 1 | 2017 | 52 | 0.040 |
Why?
|
| Serum Albumin | 2 | 2009 | 104 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 21 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 161 | 0.040 |
Why?
|
| Leptin | 1 | 2017 | 80 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 652 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 2791 | 0.040 |
Why?
|
| Microcomputers | 1 | 2016 | 32 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 1056 | 0.040 |
Why?
|
| Controlled Before-After Studies | 1 | 2016 | 4 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 330 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 65 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 176 | 0.030 |
Why?
|
| Phenotype | 1 | 2019 | 947 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 710 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.030 |
Why?
|
| Monitoring, Ambulatory | 1 | 2016 | 84 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2015 | 37 | 0.030 |
Why?
|
| Testosterone | 1 | 2016 | 96 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 170 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2017 | 206 | 0.030 |
Why?
|
| Heart Failure | 1 | 2004 | 1180 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2018 | 276 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 474 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 369 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 442 | 0.030 |
Why?
|
| Glutarates | 2 | 2005 | 6 | 0.030 |
Why?
|
| Body Composition | 1 | 2016 | 119 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 649 | 0.030 |
Why?
|
| Apolipoprotein C-III | 2 | 2005 | 12 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2007 | 202 | 0.030 |
Why?
|
| Critical Illness | 1 | 2016 | 191 | 0.030 |
Why?
|
| Prenatal Diagnosis | 1 | 2015 | 73 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 122 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 179 | 0.030 |
Why?
|
| Sleep | 1 | 2016 | 263 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2015 | 371 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 57 | 0.030 |
Why?
|
| Lithium | 1 | 2014 | 76 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 17 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 191 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2014 | 37 | 0.030 |
Why?
|
| DNA Primers | 2 | 2004 | 302 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2012 | 2007 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 77 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 396 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2012 | 51 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2012 | 69 | 0.030 |
Why?
|
| Cognition | 1 | 2016 | 513 | 0.030 |
Why?
|
| Iontophoresis | 1 | 2012 | 7 | 0.030 |
Why?
|
| Genotype | 2 | 2005 | 786 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2013 | 186 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2012 | 42 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2006 | 786 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2012 | 64 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2007 | 498 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 562 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 324 | 0.020 |
Why?
|
| Light | 1 | 2012 | 152 | 0.020 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2011 | 13 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2011 | 16 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2011 | 18 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 1033 | 0.020 |
Why?
|
| Superoxides | 1 | 2011 | 70 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1047 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 2891 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2800 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3187 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 149 | 0.020 |
Why?
|
| Vitamin A | 1 | 2011 | 111 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 134 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 120 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2010 | 28 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 682 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2010 | 47 | 0.020 |
Why?
|
| Neutrophil Infiltration | 1 | 2010 | 35 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 38 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 47 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 280 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2014 | 1692 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2010 | 55 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1426 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 266 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2009 | 14 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 453 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 509 | 0.020 |
Why?
|
| Northern Territory | 1 | 2008 | 3 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 782 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 514 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 954 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 370 | 0.020 |
Why?
|
| Age of Onset | 1 | 2008 | 188 | 0.020 |
Why?
|
| Fluorescein Angiography | 1 | 2008 | 57 | 0.020 |
Why?
|
| Glutamine | 1 | 2008 | 45 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2009 | 191 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 137 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 659 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 102 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1641 | 0.020 |
Why?
|
| Systole | 1 | 2007 | 149 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2008 | 285 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2008 | 284 | 0.020 |
Why?
|
| Malaysia | 1 | 2006 | 6 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1200 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2006 | 14 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2006 | 26 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 55 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 91 | 0.020 |
Why?
|
| Pedigree | 1 | 2006 | 159 | 0.020 |
Why?
|
| Anthropometry | 1 | 2006 | 64 | 0.020 |
Why?
|
| South Carolina | 2 | 2003 | 2752 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 291 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2005 | 50 | 0.020 |
Why?
|
| Copper Sulfate | 1 | 2005 | 4 | 0.020 |
Why?
|
| Dicarboxylic Acids | 1 | 2005 | 16 | 0.020 |
Why?
|
| Hepatitis | 1 | 2005 | 25 | 0.020 |
Why?
|
| Urban Population | 1 | 2006 | 255 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 241 | 0.020 |
Why?
|
| Catalysis | 1 | 2005 | 123 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2008 | 448 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 56 | 0.020 |
Why?
|
| Family | 1 | 2006 | 293 | 0.010 |
Why?
|
| Weight Gain | 1 | 2005 | 135 | 0.010 |
Why?
|
| Cryptoxanthins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Xanthophylls | 1 | 2003 | 4 | 0.010 |
Why?
|
| Western Australia | 1 | 2003 | 4 | 0.010 |
Why?
|
| Guanine | 1 | 2003 | 21 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2077 | 0.010 |
Why?
|
| Adenine | 1 | 2003 | 46 | 0.010 |
Why?
|
| Body Constitution | 1 | 2003 | 24 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 540 | 0.010 |
Why?
|
| Menopause | 1 | 2003 | 47 | 0.010 |
Why?
|
| Private Practice | 1 | 2002 | 19 | 0.010 |
Why?
|
| Uterus | 1 | 2003 | 77 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2002 | 23 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 948 | 0.010 |
Why?
|
| Organ Size | 1 | 2003 | 242 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2003 | 71 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2005 | 301 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 489 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 2689 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 1015 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 672 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 2083 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2002 | 703 | 0.010 |
Why?
|